

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

**CHANGE OF EXECUTIVE DIRECTORS;
CHANGE IN COMPOSITION OF BOARD COMMITTEES; AND
APPOINTMENT OF PRESIDENT**

The Board hereby announces that, with effect from 26 August 2025, (1) Mr. Tao Ran has resigned as an executive Director and a member of the Executive Committee; (2) Mr. Cheng Jie has been appointed as an executive Director, the President, and a member of the Executive Committee and the Corporate Governance Committee; and (3) Mdm. Deng Rong has resigned as a member of the Corporate Governance Committee.

RESIGNATION OF EXECUTIVE DIRECTOR AND MEMBER OF THE EXECUTIVE COMMITTEE

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) hereby announces that, with effect from 26 August 2025, Mr. Tao Ran (“**Mr. Tao**”) has resigned as an executive Director and a member of the executive committee of the Company (the “**Executive Committee**”) due to other work arrangements. Mr. Tao has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Tao for his invaluable contributions to the Company and the Board.

APPOINTMENT OF EXECUTIVE DIRECTOR, PRESIDENT AND MEMBER OF THE EXECUTIVE COMMITTEE AND THE CORPORATE GOVERNANCE COMMITTEE

The Board announces that, with effect from 26 August 2025, Mr. Cheng Jie (“**Mr. Cheng**”) has been appointed as an executive Director, the president of the Company (the “**President**”) and a member of each of the Executive Committee and the corporate governance committee of the Company (the “**Corporate Governance Committee**”).

Mr. Cheng Jie, aged 46, has been appointed as an executive Director, the President and a member of each of the Executive Committee and Corporate Governance Committee on 26 August 2025. He is currently the director of certain subsidiaries of the Company. He has been serving as the chairman of Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”, a subsidiary of the Company, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000423)) since September 2024. He served as the 999 Ganmaoling product manager and product director, OTC sales and marketing director, deputy general manager of marketing center, and general manager of professional brands division of China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司) (a subsidiary of the Company, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000999)) from July 2003 to January 2022. He has also served as the executive director of Aino (China) Pharmaceutical Co., Ltd. (澳諾(中國)製藥有限公司) from December 2019 to January 2022, director and general manager of Sanjiu Sanofi (Shenzhen) Health Industry Co., Ltd (三九賽諾菲(深圳)健康產業有限公司) from January 2017 to January 2022, and the president of Dong-E-E-Jiao from January 2022 to September 2024. Mr. Cheng was awarded the title of National Model Worker in 2025, Taishan Industrial Leadership Talent (Business Management Category) in 2023, Shandong Province Model Worker in 2023, etc. Mr. Cheng graduated from Shenyang Pharmaceutical University in the PRC in July 2003 with a Bachelor’s degree in Science. He holds the title of senior engineer.

There is no service contract entered into between Mr. Cheng and the Company for his position as an executive Director. He has no fixed term of service with the Company, but he will be subject to retirement by rotation and re-election at annual general meetings of the Company pursuant to the articles of association of the Company. Mr. Cheng shall hold office until the next annual general meeting of the Company after his appointment and shall then be eligible for re-election at such meeting. Thereafter, Mr. Cheng shall be subject to retirement by rotation at least once every three years at the annual general meeting pursuant to the articles of association of the Company. Mr. Cheng will not receive any director’s emolument from the Company. He is entitled to pre-tax basic monthly salary of RMB84,000 from the Company based on his position, duties and responsibilities, as well as discretionary bonus and term-wide incentives based on the results performance of the Company and himself.

As at the date of this announcement, Mr. Cheng does not have any interests in the shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Mr. Cheng have confirmed that (i) he has and had no other relationships with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) he does not currently hold any other position with the Company or any of its subsidiaries; (iii) he has not held any directorship in other Hong Kong or overseas listed public companies in the last three years; (iv) there are no other matters relating to the aforesaid appointment that need to be brought to the attention of holders of securities of the Company; and (v) there is no other information relating to the aforesaid appointment to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

Following the appointment of Mr. Cheng as the President, the Company has complied with code provision C.2.1 of Part 2 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules.

The Board takes this opportunity to extend a warm welcome to Mr. Cheng for the appointments.

RESIGNATION OF MEMBER OF THE CORPORATE GOVERNANCE COMMITTEE

The Board further announces that with effect from 26 August 2025, Mdm. Deng Rong, currently an executive Director and the chief financial officer of the Company, has resigned as a member of the Corporate Governance Committee.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

Hong Kong, 26 August 2025

As at the date of this announcement and after the aforesaid changes, the Board comprises Mr. Bai Xiaosong as chairman and executive director of the Company; Mr. Cheng Jie and Mdm. Deng Rong as executive directors of the Company; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive directors of the Company and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive directors of the Company.